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prior to mobilization and progression free survival as well as overall
survival. Conclusion:We conclude that 1) degree of plasma cell BM
inﬁltration before mobilization did not predict for transplant out-
comes and 2) increased plasma cell BM inﬁltration before mobiliza-
tion adversely affect the efﬁciency of stem cell mobilization. Thus,
pre-transplant cytoreductive therapy improves stem cell collection
efﬁciency but did not affect the transplant outcomes.
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ID/KLH ACTIVE IMMUNOTHERAPY (FAVID) FOLLOWING HIGH DOSE
THERAPY (HDT) AND AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT) FOR NON-HODGKIN’S LYMPHOMA (NHL)
Holman, P.P.1, deMagalhaes-Silverman, M.2, Corringham, S.1,
Castro, J.E.1, Carrier, E.1, Lane, T.1, Gold, D.3, Ball, E.1 1Moores
UCSD Cancer Center, Blood and Marrow Transplantation Division, La
Jolla, CA; 2University of Iowa, Iowa City, IA; 3Favrille, Inc, San Diego,
CA.
Sixteen patients with NHL were treated in a pilot study evalu-
ating the feasibility, safety and potential efﬁcacy of patient speciﬁc
idiotype immunization (Id/KLH Active Immunotherapy) follow-
ing HDT and ASCT. FavId was administered along with GM-
CSF. Two patients continue in active treatment; 1 mantle cell
lymphoma (MCL) and 1 transformed NHL (TL) and are not
reported here. Of the remaining 14 patients, 8 had MCL, 4 had
follicular lymphoma (FL), 1 had small lymphocytic lymphoma
(SLL) and 1 had TL. The median number of prior regimens for all
patients was 3 (range 1-10). For MCL patients, the median number
of prior regimens was 2.5 (range 1-4) which included CHOP and
hyperCVAD /- rituximab (R). FL patients received a variety of
regimens including ﬂudarabine, CVP, CHOP, R alone or in com-
bination and Zevalin. All MCL and FL patients received HDT
with BEAM except 1 who received CEB. The TL patient received
Bexxar, Cy/VP-16. Idiotype immunizations were begun 3 months
following HDT/ASCT. Of the 6 patients with MCL who achieved
a CR following transplant, 5 remain in continuing CR (CCR)
between 27 and 60 months post-transplant. The 6th patient re-
lapsed after 40 months. Of the 3 patients with FL who obtained a
CR, 2 continue in CR at 41-58 months post-transplant. The 3rd FL
patient died from MDS at 34 months. Of the 5 MCL patients with
a continuing CR, 4 developed cellular anti-Id and anti-KLH re-
sponses and one was not tested. The patient who relapsed after 40
months also had both anti-Id and anti-KLH cellular responses. Of
the 3 FL patients who obtained a durable CR, 2 developed anti-Id
and anti-KLH cellular responses and the 3rd was not tested. Id/
KLH Active Immunotherapy was well tolerated with injection site
reactions being the most commonly reported adverse effects. GM-
CSF related myalgias were also commonly reported. We conclude
that Id/KLH Active Immunotherapy following HDT and ASCT
for MCL and FL is feasible, safe, associated with idiotype speciﬁc
immune responses and may be associated with prolonged remis-
sions, even in patients heavily pretreated with very immunosup-
pressive regimens.
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USE OF A NOVEL ORGANIC ARSENIC (ZIO-101) AFTER AUTOTRANS-
PLANTS FOR MULTIPLE MYELOMA
Hussein, M.A.1, Belch, A.2, Boccia, R.V.3, Barlogie, B.4, Campbell, R.5,
Boise, L.H.6, Schwartz, B.7, Gale, R.P.7, Berenson, J.P.5 1Cleveland
Cancer Center, Cleveland, OH; 2Cross Cancer Institute, Edmonton, AB,
Canada; 3Center for Cancer and Blood Disorders, Bethesda, MD; 4My-
eloma Institute for Research and Therapy, Little Rock, AR; 5Institute for
Myeloma and Bone Cancer Research, West Hollywood, CA; 6University
of Miami School of Medicine, Miami, FL; 7ZIOPHARM Oncology, Inc.,
Charlestown, MA.
Background Autotransplants are commonly used to treat mul-
tiple myeloma; unfortunately most recipients relapse. Subsequent
therapy is often difﬁcult because of limited bone marrow reserve.
ZIO-101, a new organic arsenic, is active against human myeloma
cell lines in vitro and in scid mice with human myeloma xenografts.
ZIO-101 is active in phase-1 trials in multiple myeloma and has
little bone marrow toxicity. Because of these features, ZIO-101 is
a good candidate for therapy of multiple myeloma after an auto-
transplant.
Method Phase-1 and -2 trials in persons with multiple myeloma.
Pharmacokinetic (PK) studies.
Subjects N13. Median age, 57 y (range, 41-78 y); 5 were male.
All had advanced myeloma: median N prior therapies, 6 (range,
2-12). 6 received 1 prior autotransplants.
Dosimetry 4 cohorts received 25 courses of ZIO-101 with a
starting dose of 78 mg/me2/d IV and a maximum administered
dose (MAD) of 420 mg/me2/d. 2 schedules were studied: (1) daily
for 5 consecutive d every 4 w; and (2) twice weekly for 3 w every
4 w. Median N cycles was 2 (range, 1-10). Adverse events at doses
 300 mg/me2/d were modest and there was no clinically-impor-
tant bone marrow toxicity or QTc-prolongation. Estimated max-
imum tolerated dose (MTD) is 300-420 mg/me2/d.
Activity Activity was seen including subjects receiving a prior
autotransplant. Details will be presented.
PK Studies at 420 mg/me2/d showed a tmax  1 h (SD  0.9),
Cmax  1.06 g/mL (SD  0.07 g/mL), t1/2  17.8 h (SD 
1.4 h) and AUC0-  25.9 g  h/mL (SD  0.8 g  h/mL).
Conclusions ZIO-101 is safe in persons with multiple myeloma
at doses 300-420 mg/me2/d (MTD) and may be especially useful
posttransplant because of modest bone marrow suppression.
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IMPROVED OUTCOME OF PATIENTS WITH MANTLE CELL LYMPHOMA
(MCL) IN FIRST REMISSION (CR1) AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Kassim, A.1, Jagasia, M.1, Dixon, S.1, Chinratanalab, W.1,2,
Morgan, D.1,2, Ruffner, K.1,2, Greer, J.1, Stein, R.1, Engelhardt, B.1,
Goodman, S.1,2, Schuening, F.1 1Vanderbilt University, Nashville, TN;
2Veteran Administration, Nashville, TN.
Introduction: MCL, accounts for 5% of non-Hodgkin lym-
phoma and is characterized by t(11;14) translocation leading to
Cyclin D1 over expression. It is currently considered incurable,
with a median overall survival (OS) of 3 to 4 years from diagnosis.
Results of hematopoietic stem cell transplant (HSCT) are mixed,
with earlier studies showing no survival advantage over conven-
tional chemotherapy, but more recent studies, suggesting better
outcome. The optimal timing of HSCT for patients (pts) with
MCL is not known.
Methods: Between 2/1994 and 5/2006, 70 consecutive pts with
MCL underwent an autologous (auto) (n  56) or allogeneic (allo)
[n  14 (11-myeloablative; 3-reduced intensity regimens-RIC)].
Most pts had stage IV disease 50/70 (71%). 46/70 (66%) pts had
bone marrow (BM) involvement. Conditioning regimen for auto
HSCT consisted mainly of CBV (cyclophosphamide, BCNU and
etoposide). Allo HSCT regimens included ablative (cyclophosph-
amide/VP16  TBI); or RIC (ﬂudarabine/busulfan or ﬂudarabine/
TBI). GVHD prophylaxis consisted of cyclosporine (CSA) and
methotrexate or CSA/mycophenolate mofetil. 56 pts received BM,
10-peripheral blood (PB) and 4 (BM/PB).
Results: Median age at transplant was 56 years (yrs) (range
35-67). Median follow up was 2.1 yrs (range, 0.01-9.1). 50% of the
pts had at least 2 prior therapies prior to transplant. 55/70 pts had
a response after transplant (52-complete remission, and 3 partial
responses). 4/70 pts had no response and progressed. 35 pts are
alive (27-autologous; 8-allogeneic), of which 17 pts relapsed. 35
patients are dead: progressive disease, 23; sepsis/infection, 5; sec-
ondary malignancy, 2; pulmonary embolism, 1; and other causes, 4.
Median OS was 3.5 yrs (95% CI 2.4 to 4.6) with no signiﬁcant
difference between auto and allo (median not reached) pts (P 
0.78). Median progression free survival (PFS) was 3.5 yrs (95% CI
0.6 to 6.3), and was not different for auto or allo (median not
reached) HSCT (P0.82). 25/70 (36%) patients underwent
HSCT (auto-24, allo-1) in CR1. OS of these patients was superior
compared to pts transplanted later in their disease course (not
reached vs. 2.5 yrs, P0.023).
Conclusion: Patients transplanted in CR1 have a better overall
survival compared to being transplanted later in the disease course.
Pts not achieving CR1 or presenting with recurrence of disease
should be considered for early transplant. The optimal type of
transplant in these patients needs to be further validated.
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